|
IL126999A
(en)
|
1996-07-24 |
2002-03-10 |
Warner Lambert Co |
Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
|
|
JP3878809B2
(ja)
*
|
1997-09-18 |
2007-02-07 |
ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー |
ガバペンチン類似体を製造するための新規な立体選択的方法
|
|
US6984659B2
(en)
|
1997-11-18 |
2006-01-10 |
Klinikum Der Albert-Ludwigs Universitaet |
2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
|
|
DE19751062A1
(de)
*
|
1997-11-18 |
1999-07-08 |
Univ Ludwigs Albert |
An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
|
|
CA2304967C
(en)
*
|
1997-12-16 |
2005-06-14 |
Warner-Lambert Company |
4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
|
|
WO2001072311A1
(en)
*
|
2000-03-28 |
2001-10-04 |
Delorenzo Robert J |
Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death
|
|
EP1361847A2
(en)
|
2000-10-06 |
2003-11-19 |
Xenoport, Inc. |
Bile-acid conjugates for providing sustained systemic concentrations of drugs
|
|
WO2002028881A1
(en)
|
2000-10-06 |
2002-04-11 |
Xenoport, Inc. |
Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
|
|
GB2368579A
(en)
*
|
2000-10-31 |
2002-05-08 |
Parke Davis & Co Ltd |
Azole pharmaceutical agents
|
|
US6818787B2
(en)
|
2001-06-11 |
2004-11-16 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
|
US7232924B2
(en)
|
2001-06-11 |
2007-06-19 |
Xenoport, Inc. |
Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
|
|
US8048917B2
(en)
|
2005-04-06 |
2011-11-01 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
|
US7420002B2
(en)
|
2001-06-11 |
2008-09-02 |
Xenoport |
Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
|
|
ATE540678T1
(de)
|
2001-06-11 |
2012-01-15 |
Xenoport Inc |
Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
|
|
US7186855B2
(en)
|
2001-06-11 |
2007-03-06 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
|
WO2003077902A1
(en)
|
2002-02-19 |
2003-09-25 |
Xenoport, Inc. |
Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
|
|
AU2003222033A1
(en)
|
2002-03-20 |
2003-10-08 |
Xenoport |
Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
|
|
WO2003099338A2
(en)
|
2002-05-17 |
2003-12-04 |
Xenoport, Inc. |
Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
|
|
US20040092498A1
(en)
*
|
2002-08-16 |
2004-05-13 |
David Blakemore |
Substituted glycine derivatives for use as medicaments
|
|
WO2004052360A1
(en)
|
2002-12-11 |
2004-06-24 |
Xenoport, Inc. |
Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
|
|
WO2004054560A1
(en)
|
2002-12-13 |
2004-07-01 |
Warner-Lambert Company Llc |
Alpha-2-delta ligand to treat lower urinary tract symptoms
|
|
CA2451267A1
(en)
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
|
KR20060119971A
(ko)
|
2003-09-11 |
2006-11-24 |
제노포트 인코포레이티드 |
Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
|
|
NZ545494A
(en)
|
2003-09-12 |
2009-10-30 |
Pfizer |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
|
|
AU2004274002B2
(en)
|
2003-09-17 |
2011-04-28 |
Arbor Pharmaceuticals, Llc |
Treating or preventing restless legs syndrome using prodrugs of GABA analogs
|
|
PT1677767E
(pt)
|
2003-10-14 |
2011-10-13 |
Xenoport Inc |
Forma cristalina de análogo de ácido gama-aminobutírico
|
|
US20050176680A1
(en)
|
2003-12-11 |
2005-08-11 |
Sepracor, Inc. |
Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
|
|
CA2584338C
(en)
|
2004-11-04 |
2013-08-06 |
Xenoport, Inc. |
Gabapentin prodrug sustained release oral dosage forms
|
|
CA2673545A1
(en)
|
2006-12-22 |
2008-07-03 |
Recordati Ireland Limited |
Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids
|
|
WO2009024615A1
(en)
*
|
2007-08-23 |
2009-02-26 |
Novartis Ag |
Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors
|
|
CA2706575C
(en)
|
2008-01-25 |
2015-07-14 |
Xenoport, Inc. |
Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
|
|
US7868043B2
(en)
|
2008-01-25 |
2011-01-11 |
Xenoport, Inc. |
Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
|
|
EP2250148B1
(en)
|
2008-01-25 |
2016-08-17 |
XenoPort, Inc. |
Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
|
|
CN105330603A
(zh)
|
2008-10-08 |
2016-02-17 |
凯飞药业公司 |
Gaba偶联物及其使用方法
|
|
WO2010084797A1
(ja)
*
|
2009-01-21 |
2010-07-29 |
第一三共株式会社 |
含ヘテロ原子化合物
|
|
US9066853B2
(en)
|
2013-01-15 |
2015-06-30 |
Warsaw Orthopedic, Inc. |
Clonidine compounds in a biodegradable fiber
|
|
CA2903000C
(en)
|
2013-01-28 |
2021-10-12 |
Hector L. Lopez |
Methods of improving tolerability, pharmacodynamics, and efficacy of .beta.-alanine and use therefor
|
|
CN112424158A
(zh)
|
2018-05-14 |
2021-02-26 |
昌郁医药公司 |
萘普生和普瑞巴林的1-(酰氧基)-烷基氨基甲酸酯药物缀合物的结晶形式
|